WGU D116 Advanced Pharmacology OA Exam Prep
Document | 2026/2027 Edition | 200 Verified Questions
WGU D116 Advanced Pharmacology OA 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously designed for nursing students
preparing for the WGU D116 Advanced Pharmacology Objective Assessment. It features 200 verified
practice questions that mirror the format and difficulty of the actual exam, complete with detailed
rationales for each answer. The content is updated to reflect the latest 2026/2027 academic guidelines,
ensuring relevance and accuracy. Each question is crafted to reinforce key pharmacological concepts,
therapeutic applications, and safety considerations essential for advanced nursing practice. This guide
is an indispensable resource for achieving a high score and mastering advanced pharmacology.
Key Features:
Pharmacokinetics and pharmacodynamics principles
Drug classifications and mechanisms of action
Therapeutic uses and adverse effects of major drug classes
Patient education and monitoring for drug therapy
Drug interactions and contraindications
Clinical application in complex patient scenarios
Updates for 2026:
- Revised to align with the latest 2026/2027 WGU D116 curriculum updates
- Incorporated new FDA-approved medications and withdrawn drugs
- Enhanced rationales with evidence-based guidelines and current research
- Added more case-based questions to reflect clinical reasoning demands
- Updated drug interaction tables and safety alerts
Abstract:
This exam preparation guide for WGU D116 Advanced Pharmacology Objective Assessment offers a rigorous and
comprehensive review of advanced pharmacological principles essential for nursing practice. With 200 verified
questions, the document systematically covers key areas including pharmacokinetics, pharmacodynamics, drug
classifications, therapeutic applications, and patient safety. Each question is accompanied by a detailed
explanation that clarifies the correct answer and discusses why the distractors are incorrect, thereby deepening the
learner's understanding. The content is updated to reflect the latest 2026/2027 academic standards, ensuring that
students are well-prepared for the current exam format. This guide is an invaluable tool for nursing students
seeking to excel in their advanced pharmacology course and pass the objective assessment with confidence.
Keywords:
Advanced Pharmacology, WGU D116, Objective Assessment, Nursing Exam Prep, Pharmacokinetics, Drug
Interactions, Clinical Pharmacology, 2026/2027
Answer Format:
Each question is presented in multiple-choice format with four options. The correct answer is clearly indicated,
followed by a comprehensive rationale explaining the underlying pharmacological principle. Additionally, each
rationale includes an analysis of why the incorrect options are not the best choices, reinforcing critical thinking and
application.
Compliance Checklist:
Aligned with WGU D116 course objectives
Page 1
, Updated to 2026/2027 academic year guidelines
100% verified answers and rationales
Covers all major drug classes and therapeutic areas
Includes clinical application and safety considerations
Suitable for self-assessment and exam readiness
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-30 Absorption, Distribution, Metabolism, 15%
Pharmacodynamics Excretion, Receptor Theory, Dose-Response
Autonomic Nervous System 31-60 Cholinergics, Anticholinergics, Adrenergics, 15%
Drugs Adrenergic Blockers
Cardiovascular Drugs 61-90 Antihypertensives, Antiarrhythmics, Cardiac 15%
Glycosides, Anticoagulants, Antiplatelets
Central Nervous System Drugs 91-120 Sedatives, Anesthetics, Antidepressants, 15%
Antipsychotics, Anticonvulsants, Opioids
Endocrine and Metabolic Drugs 121-150 Insulin, Oral Hypoglycemics, 15%
Corticosteroids, Thyroid Hormones, Bone
Metabolism Agents
Antimicrobials and 151-180 Antibiotics, Antivirals, Antifungals, 15%
Chemotherapy Antineoplastics, Immunosuppressants
Special Populations and 181-200 Pediatric, Geriatric, Pregnancy, 10%
Toxicology Renal/Hepatic Impairment, Drug Overdose
and Antidotes
Page 2
,Q1. A patient with chronic heart failure is stabilized on sacubitril/valsartan. Which
additional medication, if prescribed, would most significantly increase the risk of
angioedema due to a pharmacodynamic interaction?
A. Spiironolactone
B. Furosemide
C. Lisinopril
D. Metoprolol succinate
Correct Answer: C. Lisinopril
Rationale: Sacubitril/valsartan inhibits neprilysin, which degrades bradykinin. Adding an
ACE inhibitor like lisinopril further blocks bradykinin metabolism, markedly increasing
angioedema risk. Spironolactone, furosemide, and metoprolol do not affect bradykinin
pathways.
Why Wrong:
A - Spironolactone is a potassium-sparing diuretic and does not interact with the
bradykinin system.
B - Furosemide is a loop diuretic and does not increase angioedema risk with
sacubitril/valsartan.
D - Metoprolol is a beta-blocker and does not affect bradykinin metabolism.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 23.
Q2. A patient on warfarin is prescribed metronidazole for an anaerobic infection.
Which pharmacokinetic mechanism best explains the exaggerated anticoagulant
effect observed within 48 hours?
A. Displacement of warfarin from plasma albumin
B. Inhibition of CYP2C9, reducing warfarin clearance
C. Induction of CYP3A4, increasing warfarin metabolism
D. Antagonism of vitamin K at the epoxide reductase enzyme
Correct Answer: B. Inhibition of CYP2C9, reducing warfarin clearance
Rationale: Metronidazole is a potent inhibitor of CYP2C9, the primary enzyme
metabolizing the S-enantiomer of warfarin. This reduces warfarin clearance, leading to a
rapid rise in INR. Albumin displacement is transient and not the primary mechanism;
CYP3A4 induction would decrease effect; vitamin K antagonism is warfarin's own
mechanism.
Why Wrong:
A - Albumin displacement is a minor, transient effect and not the main cause of the
sustained INR increase.
C - CYP3A4 induction would increase warfarin metabolism and decrease
anticoagulant effect.
D - Vitamin K antagonism is the mechanism of warfarin itself, not an interaction with
Page 3
, metronidazole.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 38.
Q3. A patient with type 2 diabetes and chronic kidney disease (eGFR 25 mL/min) is
prescribed empagliflozin. Which parameter requires the most vigilant monitoring to
prevent a serious adverse outcome?
A. Serum lactate levels
B. Hemoglobin A1c
C. Urine output and serum creatinine
D. Serum sodium levels
Correct Answer: C. Urine output and serum creatinine
Rationale: In advanced CKD (eGFR <30), empagliflozin may cause volume depletion and
acute kidney injury due to osmotic diuresis and reduced renal perfusion. Monitoring urine
output and serum creatinine is essential. Lactate is not a primary concern; A1c is for
efficacy; hyponatremia is not typical.
Why Wrong:
A - Lactic acidosis is rare with empagliflozin, and monitoring lactate is not the
primary need.
B - A1c monitoring is important for efficacy, but not the most critical for adverse
outcome.
D - Hyponatremia is not a recognized major adverse effect of SGLT2 inhibitors.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 51.
Q4. A patient on long-term phenytoin therapy has a seizure recurrence. A drug level
is drawn, showing a total phenytoin concentration of 12 mcg/mL (therapeutic 10-20
mcg/mL), but the patient has hypoalbuminemia (albumin 2.5 g/dL). Which
interpretation is most accurate?
A. The free phenytoin concentration is likely subtherapeutic, so the dose should be
increased.
B. The total concentration is within the therapeutic range, so no change is needed.
C. The free phenytoin concentration is likely elevated despite the normal total level,
indicating toxicity.
D. The total concentration is falsely low due to altered metabolism, requiring a higher
dose.
Correct Answer: C. The free phenytoin concentration is likely elevated despite the
normal total level, indicating toxicity.
Rationale: Hypoalbuminemia reduces protein binding of phenytoin, increasing the free
fraction. A normal total concentration can correspond to elevated free levels, risking
toxicity. The free concentration should be measured or the dose adjusted downward.
Page 4
Document | 2026/2027 Edition | 200 Verified Questions
WGU D116 Advanced Pharmacology OA 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously designed for nursing students
preparing for the WGU D116 Advanced Pharmacology Objective Assessment. It features 200 verified
practice questions that mirror the format and difficulty of the actual exam, complete with detailed
rationales for each answer. The content is updated to reflect the latest 2026/2027 academic guidelines,
ensuring relevance and accuracy. Each question is crafted to reinforce key pharmacological concepts,
therapeutic applications, and safety considerations essential for advanced nursing practice. This guide
is an indispensable resource for achieving a high score and mastering advanced pharmacology.
Key Features:
Pharmacokinetics and pharmacodynamics principles
Drug classifications and mechanisms of action
Therapeutic uses and adverse effects of major drug classes
Patient education and monitoring for drug therapy
Drug interactions and contraindications
Clinical application in complex patient scenarios
Updates for 2026:
- Revised to align with the latest 2026/2027 WGU D116 curriculum updates
- Incorporated new FDA-approved medications and withdrawn drugs
- Enhanced rationales with evidence-based guidelines and current research
- Added more case-based questions to reflect clinical reasoning demands
- Updated drug interaction tables and safety alerts
Abstract:
This exam preparation guide for WGU D116 Advanced Pharmacology Objective Assessment offers a rigorous and
comprehensive review of advanced pharmacological principles essential for nursing practice. With 200 verified
questions, the document systematically covers key areas including pharmacokinetics, pharmacodynamics, drug
classifications, therapeutic applications, and patient safety. Each question is accompanied by a detailed
explanation that clarifies the correct answer and discusses why the distractors are incorrect, thereby deepening the
learner's understanding. The content is updated to reflect the latest 2026/2027 academic standards, ensuring that
students are well-prepared for the current exam format. This guide is an invaluable tool for nursing students
seeking to excel in their advanced pharmacology course and pass the objective assessment with confidence.
Keywords:
Advanced Pharmacology, WGU D116, Objective Assessment, Nursing Exam Prep, Pharmacokinetics, Drug
Interactions, Clinical Pharmacology, 2026/2027
Answer Format:
Each question is presented in multiple-choice format with four options. The correct answer is clearly indicated,
followed by a comprehensive rationale explaining the underlying pharmacological principle. Additionally, each
rationale includes an analysis of why the incorrect options are not the best choices, reinforcing critical thinking and
application.
Compliance Checklist:
Aligned with WGU D116 course objectives
Page 1
, Updated to 2026/2027 academic year guidelines
100% verified answers and rationales
Covers all major drug classes and therapeutic areas
Includes clinical application and safety considerations
Suitable for self-assessment and exam readiness
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-30 Absorption, Distribution, Metabolism, 15%
Pharmacodynamics Excretion, Receptor Theory, Dose-Response
Autonomic Nervous System 31-60 Cholinergics, Anticholinergics, Adrenergics, 15%
Drugs Adrenergic Blockers
Cardiovascular Drugs 61-90 Antihypertensives, Antiarrhythmics, Cardiac 15%
Glycosides, Anticoagulants, Antiplatelets
Central Nervous System Drugs 91-120 Sedatives, Anesthetics, Antidepressants, 15%
Antipsychotics, Anticonvulsants, Opioids
Endocrine and Metabolic Drugs 121-150 Insulin, Oral Hypoglycemics, 15%
Corticosteroids, Thyroid Hormones, Bone
Metabolism Agents
Antimicrobials and 151-180 Antibiotics, Antivirals, Antifungals, 15%
Chemotherapy Antineoplastics, Immunosuppressants
Special Populations and 181-200 Pediatric, Geriatric, Pregnancy, 10%
Toxicology Renal/Hepatic Impairment, Drug Overdose
and Antidotes
Page 2
,Q1. A patient with chronic heart failure is stabilized on sacubitril/valsartan. Which
additional medication, if prescribed, would most significantly increase the risk of
angioedema due to a pharmacodynamic interaction?
A. Spiironolactone
B. Furosemide
C. Lisinopril
D. Metoprolol succinate
Correct Answer: C. Lisinopril
Rationale: Sacubitril/valsartan inhibits neprilysin, which degrades bradykinin. Adding an
ACE inhibitor like lisinopril further blocks bradykinin metabolism, markedly increasing
angioedema risk. Spironolactone, furosemide, and metoprolol do not affect bradykinin
pathways.
Why Wrong:
A - Spironolactone is a potassium-sparing diuretic and does not interact with the
bradykinin system.
B - Furosemide is a loop diuretic and does not increase angioedema risk with
sacubitril/valsartan.
D - Metoprolol is a beta-blocker and does not affect bradykinin metabolism.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 23.
Q2. A patient on warfarin is prescribed metronidazole for an anaerobic infection.
Which pharmacokinetic mechanism best explains the exaggerated anticoagulant
effect observed within 48 hours?
A. Displacement of warfarin from plasma albumin
B. Inhibition of CYP2C9, reducing warfarin clearance
C. Induction of CYP3A4, increasing warfarin metabolism
D. Antagonism of vitamin K at the epoxide reductase enzyme
Correct Answer: B. Inhibition of CYP2C9, reducing warfarin clearance
Rationale: Metronidazole is a potent inhibitor of CYP2C9, the primary enzyme
metabolizing the S-enantiomer of warfarin. This reduces warfarin clearance, leading to a
rapid rise in INR. Albumin displacement is transient and not the primary mechanism;
CYP3A4 induction would decrease effect; vitamin K antagonism is warfarin's own
mechanism.
Why Wrong:
A - Albumin displacement is a minor, transient effect and not the main cause of the
sustained INR increase.
C - CYP3A4 induction would increase warfarin metabolism and decrease
anticoagulant effect.
D - Vitamin K antagonism is the mechanism of warfarin itself, not an interaction with
Page 3
, metronidazole.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 38.
Q3. A patient with type 2 diabetes and chronic kidney disease (eGFR 25 mL/min) is
prescribed empagliflozin. Which parameter requires the most vigilant monitoring to
prevent a serious adverse outcome?
A. Serum lactate levels
B. Hemoglobin A1c
C. Urine output and serum creatinine
D. Serum sodium levels
Correct Answer: C. Urine output and serum creatinine
Rationale: In advanced CKD (eGFR <30), empagliflozin may cause volume depletion and
acute kidney injury due to osmotic diuresis and reduced renal perfusion. Monitoring urine
output and serum creatinine is essential. Lactate is not a primary concern; A1c is for
efficacy; hyponatremia is not typical.
Why Wrong:
A - Lactic acidosis is rare with empagliflozin, and monitoring lactate is not the
primary need.
B - A1c monitoring is important for efficacy, but not the most critical for adverse
outcome.
D - Hyponatremia is not a recognized major adverse effect of SGLT2 inhibitors.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 51.
Q4. A patient on long-term phenytoin therapy has a seizure recurrence. A drug level
is drawn, showing a total phenytoin concentration of 12 mcg/mL (therapeutic 10-20
mcg/mL), but the patient has hypoalbuminemia (albumin 2.5 g/dL). Which
interpretation is most accurate?
A. The free phenytoin concentration is likely subtherapeutic, so the dose should be
increased.
B. The total concentration is within the therapeutic range, so no change is needed.
C. The free phenytoin concentration is likely elevated despite the normal total level,
indicating toxicity.
D. The total concentration is falsely low due to altered metabolism, requiring a higher
dose.
Correct Answer: C. The free phenytoin concentration is likely elevated despite the
normal total level, indicating toxicity.
Rationale: Hypoalbuminemia reduces protein binding of phenytoin, increasing the free
fraction. A normal total concentration can correspond to elevated free levels, risking
toxicity. The free concentration should be measured or the dose adjusted downward.
Page 4
